CoChat

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Open access

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

Abstract

TREM2 is an innate immune receptor expressed on the surface of microglia. Loss-of-function mutations of TREM2 are associated with increased risk of Alzheimer's disease (AD). TREM2 is a type-1 protein with an ectodomain that is proteolytically cleaved and released into the extracellular space as a soluble variant (sTREM2), which can be measured in the cerebrospinal fluid (CSF). In this cross-sectional multicenter study, we investigated whether CSF levels of sTREM2 are changed during the clinical course of AD, and in cognitively normal individuals with suspected non-AD pathology (SNAP). CSF sTREM2 levels were higher in mild cognitive impairment due to AD than in all other AD groups and controls. SNAP individuals also had significantly increased CSF sTREM2 compared to controls. Moreover, increased CSF sTREM2 levels were associated with higher CSF total tau and phospho-tau181P, which are markers of neuronal degeneration and tau pathology. Our data demonstrate that CSF sTREM2 levels are increased in the early symptomatic phase of AD, probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201506123

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CSF sTREM2 is associated with age Scatter plot representing CSF sTREM2 as a function of age in the different diagnostic groups. Solid lines indicate the linear regression for each of the groups; the dashed line indicates the linear regression within the entire sample. P‐values were assessed by Pearson product‐moment correlations..
Figure 1 CSF sTREM2 is associated with age Scatter plot representing CSF sTREM2 as a function of age in the different diagnostic groups. Solid lines indicate the linear regression for each of the groups; the dashed line indicates the linear regression within the entire sample. P‐values were assessed by Pearson product‐moment correlations..CC BY · PubMed Central
Figure 2 CSF sTREM2 levels in the different diagnostic groups Scatter plot showing levels of CSF sTREM2 (log‐transformed) in the different diagnostic groups. Red bars represent the mean and the 95% CI. P‐values were assessed by a linear mixed model adjusted by age and gender (fixed effects) and center (random effects).
Figure 2 CSF sTREM2 levels in the different diagnostic groups Scatter plot showing levels of CSF sTREM2 (log‐transformed) in the different diagnostic groups. Red bars represent the mean and the 95% CI. P‐values were assessed by a linear mixed model adjusted by age and gender (fixed effects) and center (random effects).CC BY · PubMed Central
Figure 3 Association of CSF sTREM2 with the AD CSF core biomarkers A–FScatter plots representing association of CSF sTREM2 with T‐tau (A, B), P‐tau181P (C, D), and Aβ1–42 (E, F) in the control and AD continuum groups. Each point depicts the value of CSF sTREM2 of a subject, and the solid lines indicate the regression line for each of the groups calculated by a linear mixed‐effects model adjusted by age and gender (fixed effects) and center (random effects). The standardized regression coefficients (β) and the P‐values are also shown. The sample contained some extreme values of T‐tau and P‐tau181P. We did not exclude any value, but we performed a bootstrapping for each association in order to ensure that the associations were not driven by these extreme values.
Figure 3 Association of CSF sTREM2 with the AD CSF core biomarkers A–FScatter plots representing association of CSF sTREM2 with T‐tau (A, B), P‐tau181P (C, D), and Aβ1–42 (E, F) in the control and AD continuum groups. Each point depicts the value of CSF sTREM2 of a subject, and the solid lines indicate the regression line for each of the groups calculated by a linear mixed‐effects model adjusted by age and gender (fixed effects) and center (random effects). The standardized regression coefficients (β) and the P‐values are also shown. The sample contained some extreme values of T‐tau and P‐tau181P. We did not exclude any value, but we performed a bootstrapping for each association in order to ensure that the associations were not driven by these extreme values.CC BY · PubMed Central
Figure 4 CSF sTREM2 levels in cognitively normal SNAPs and in MCI‐noAD Scatter plot showing CSF sTREM2 levels across different groups of cognitively normal individuals: SNAP, suspected non‐AD pathophysiology (n = 39); control subjects (n = 150); and preclinical AD (n = 63).Differences in CSF sTREM2 in MCI‐AD (n = 111) compared to MCI‐noAD (n = 103) and controls (n = 150).Data information: The red bars represent the mean and the 95% CI. P‐values were assessed by a linear mixed‐effects model adjusting by age and gender (fixed effects) and center (random effect).
Figure 4 CSF sTREM2 levels in cognitively normal SNAPs and in MCI‐noAD Scatter plot showing CSF sTREM2 levels across different groups of cognitively normal individuals: SNAP, suspected non‐AD pathophysiology (n = 39); control subjects (n = 150); and preclinical AD (n = 63).Differences in CSF sTREM2 in MCI‐AD (n = 111) compared to MCI‐noAD (n = 103) and controls (n = 150).Data information: The red bars represent the mean and the 95% CI. P‐values were assessed by a linear mixed‐effects model adjusting by age and gender (fixed effects) and center (random effect).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 574

Metadata

Authors
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., Sánchez‐Valle, R., Antonell, A., Rami, L., Molinuevo, J. L., Brosseron, F., Traschütz, A., Heneka, M. T., Struyfs, H., Engelborghs, S., Sleegers, K., Van Broeckhoven, C., Zetterberg, H., Nellgård, B., Blennow, K., Crispin, A., Ewers, M., & Haass, C.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • Munich Cluster for Systems Neurology (DE)
  • LMU Klinikum (DE)
  • Universitat Autònoma de Barcelona (ES)
  • Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES)
  • Hospital Clínic de Barcelona (ES)
  • Pasqual Maragall Foundation (ES)
  • University Hospital Bonn (DE)
  • University of Antwerp (BE)
  • UCL Queen Square Institute of Neurology (GB)
  • University of Gothenburg (SE)
  • Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (DE)
Corresponding author
  • Ewers, Michael
  • Haass, Christian
Venue
EMBO Molecular Medicine
Published
2016-03-03
Volume
8
Issue
5
Pages
466-476
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2289098957
Cited by
522
References
54
Citations by year
2026: 46 · 2025: 45 · 2024: 66 · 2023: 52 · 2022: 59 · 2021: 63 · 2020: 67 · 2019: 42 · 2018: 43 · 2017: 27 · 2016: 11
FWCI
22.46
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, cc-by)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • DZNE Pub (submittedVersion, cc-by)
Funders
  • European Commission (PCIG12‐GA‐2012‐334259)
  • European Research Council (FP7/2007–2013, 321366)
  • Deutsche Forschungsgemeinschaft (115372)
  • Cure Alzheimer's Fund
  • MetLife Foundation Award
  • Swedish Research Council
  • Torsten Söderberg Foundation
  • Royal Swedish Academy of Sciences
  • Knut and Alice Wallenberg Foundation
  • Frimurarestiftelsen (115372)
  • University Research Fund of the University of Antwerp
  • Institute Born‐Bunge
  • Foundation for Alzheimer Research
  • Neurosearch Antwerp
  • Research Foundation—Flanders
  • Agency for Innovation by Science and Technology
  • Interuniversity Attraction Poles (IAP) Program of the Belgian Science Policy Office
  • Flemish Government Methusalem Excellence Program, Belgium
  • Flanders Impulse Program on Networks for Dementia Research
  • EU Joint Program for Neurodegenerative Disease Research (321366)
  • EU/EFPIA Innovative Medicines Initiative Joint Undertaking (115372)
  • Belgian Science Policy Office Interuniversity Attraction Poles Program
  • Flanders Government Initiated Impulse Program on Networks for Dementia Research
  • Flemish government Initiated Methusalem Excellence Program
  • University of Antwerp Research Fund, Belgium
  • Janssen
  • ADx Neurosciences
  • Innogenetics/Fujirebio Europe
  • Lundbeck
  • Pfizer (115372)
  • Novartis
  • UCB
  • Roche Diagnostics
  • Nutricia/Danone (115372)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
soluble TREM2, sTREM2, TREM2, microglial activation, Alzheimer's disease, cerebrospinal fluid biomarkers, mild cognitive impairment, tau protein, neuronal injury, innate immunity, early Alzheimer's disease, cognitively normal individuals
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cerebrospinal Fluid, Cross-Sectional Studies, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Receptors, Immunologic, Biomarkers, Microglia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers. https://app.cochat.ai/papers/10.15252/emmm.201506123
The paper
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., Sánchez‐Valle, R., Antonell, A., Rami, L., Molinuevo, J. L., Brosseron, F., Traschütz, A., Heneka, M. T., Struyfs, H., Engelborghs, S., . . . Haass, C. (2016). sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201506123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.